Stocks to Watch. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are archrivals thanks to their dueling drugs for weight loss, Zepbound and ...

Shares of Eli Lilly & Co. LLY slid 1.65% to $909.32 Thursday, on what proved to be an all-around favorable trading session ...

The success of Eli Lilly’s Zepbound, a challenger to Novo’s Wegovy, has prompted comparisons to a similar scenario, when ...

Eli Lilly said on Tuesday Japan's health ministry has approved donanemab, its drug for Alzheimer's disease, providing ...

Eli Lilly & Co. closed $48.10 short of its 52-week high ($972.53), which the company achieved on August 22nd.

To fight off compounding pharmacies, Eli Lilly wants access to medical records of patients who used copycat products.

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Sen. Bernie Sanders’ aggressive targeting of Danish drugmaker Novo Nordisk’s Ozempic and Wegovy pricing, and not Eli Lilly’s ...

Investors with a lot of money to spend have taken a bullish stance on Eli Lilly LLY. And retail traders should know. We ...

On Thursday, Eli Lilly And Co (LLY) stock saw a decline, ending the day at $909.32 which represents a decrease of $-15.24 or -1.65% from the prior close of $924.56. The stock opened at $920.26 and ...

New public and private entrants are emerging to challenge the leading positions of Novo Nordisk NVO and Eli Lilly LLY in a ...